Amgen’s MariTide leads the pack, while other candidates face setbacks in the competitive GLP-1RA landscape.
Amgen’s MariTide leads the pack, while other candidates face setbacks in the competitive GLP-1RA landscape.
New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
Memorial Sloan Kettering researchers uncover how pancreatic cancer cells suppress immune triggers by manipulating genetic elements.
Gilead’s twice-yearly injectable PrEP shows near-perfect efficacy, prompting global access initiatives and a rethinking of HIV prevention strategies.
A new research center and FDA-backed diversity mandates aim to reshape clinical trial equity and representation across the …
Arvinas and Pfizer’s vepdegestrant becomes the first oral PROTAC therapy approved for ER-positive breast cancer, opening new avenues …
New CMS rules signal a turning point for AI-powered cardiac diagnostics, paving the way for broader clinical adoption …
A landmark Phase 3 clinical trial led by researchers at Mass General Brigham has demonstrated that inebilizumab, a …
On November 14, 2024, PDS Biotech announced significant updates to its Phase 3 clinical trial design for its …
On November 13, 2024, the U.S. Food and Drug Administration (FDA) approved a novel gene therapy for aromatic …